Product Description
For osteoporosis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05225857)
Mechanisms of Action: DKK1 Inhibitor, Sclerostin Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Angitia Biopharmaceuticals
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Bulgaria, Denmark, Estonia, Poland, Ukraine, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteoporosis, Postmenopausal
Phase 1: Osteoporosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05225857 |
NCT05225857 | P1 |
Completed |
Osteoporosis |
2024-01-13 |
69% |
2024-02-06 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06577935 |
ARTEMIS | P2 |
Active, not recruiting |
Osteoporosis, Postmenopausal |
2026-12-01 |
50% |
2026-01-08 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2024-515610-41-00 |
ACT23-001 | P2 |
Not yet recruiting |
Osteoporosis, Postmenopausal |
2027-08-31 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/12/2026 |
News Article |
Angitia Biopharmaceuticals Announces Dosing of First Participant in Phase 2 IDUN Trial of AGA2115 for the Treatment of Osteogenesis Imperfecta |
|
01/05/2026 |
News Article |
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis |
|
09/30/2024 |
News Article |
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024 |
|
09/16/2024 |
News Article |
Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024 |